← Back to Screener
Opus Genetics, Inc. Common Stock (IRD)
Price$4.03
Value ScoreD
Growth ScoreD
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)81.28%
Price vs S&P 500 (4W)-19.23%
VGM Score41.20
Market Capitalization$328.02M
All Metrics
Book Value / Share (Quarterly)$0.22
P/TBV (Annual)20.69x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-29.11%
Cash Flow / Share (Quarterly)$-0.55
Price vs S&P 500 (YTD)92.34%
Net Profit Margin (TTM)-892.36%
EPS (TTM)$-1.32
10-Day Avg Trading Volume0.89M
EPS Excl Extra (TTM)$-1.32
EPS (Annual)$-0.80
ROI (Annual)-300.97%
Gross Margin (Annual)87.50%
Net Profit Margin (5Y Avg)-2097.75%
Cash / Share (Quarterly)$0.84
Revenue Growth QoQ (YoY)-50.64%
ROA (Last FY)-98.70%
Revenue Growth TTM (YoY)-12.22%
EBITD / Share (TTM)$-0.57
ROE (5Y Avg)-156.92%
Operating Margin (TTM)-359.13%
Cash Flow / Share (Annual)$-0.50
P/B Ratio21.37x
P/B Ratio (Quarterly)9.03x
Net Income / Employee (Annual)$-1,836,700
EV / Revenue (TTM)22.47x
Net Interest Coverage (TTM)-32.83x
ROA (TTM)-222.99%
EV / EBITDA (TTM)9.26x
EPS Incl Extra (Annual)$-0.80
Current Ratio (Annual)6.43x
Quick Ratio (Quarterly)6.71x
3-Month Avg Trading Volume0.97M
52-Week Price Return303.00%
Revenue / Employee (TTM)$443,800
Tangible BV / Share (Quarterly)$38.85
P/S Ratio (Annual)23.11x
Asset Turnover (Annual)0.28x
52-Week High$5.81
Operating Margin (5Y Avg)-938.76%
EPS Excl Extra (Annual)$-0.80
26-Week Price Return89.20%
Quick Ratio (Annual)6.20x
13-Week Price Return-15.51%
Total Debt / Equity (Annual)0.07x
Current Ratio (Quarterly)7.13x
Enterprise Value$269.26M
Asset Turnover (TTM)0.25x
Book Value / Share Growth (5Y)-53.37%
Revenue / Employee (Annual)$525,800
Pretax Margin (Annual)-349.33%
Cash / Share (Annual)$0.65
3-Month Return Std Dev69.06%
Net Income / Employee (TTM)$-3,960,400
ROE (Last FY)-323.11%
Net Interest Coverage (Annual)-0.91x
EPS Basic Excl Extra (Annual)$-0.80
Receivables Turnover (TTM)3.21x
Total Debt / Equity (Quarterly)0.07x
EPS Incl Extra (TTM)$-1.32
Receivables Turnover (Annual)3.18x
ROI (TTM)-301.00%
P/S Ratio (TTM)27.37x
Pretax Margin (5Y Avg)-2097.58%
Revenue / Share (Annual)$0.23
Tangible BV / Share (Annual)$20.08
Price vs S&P 500 (52W)278.63%
Year-to-Date Return100.50%
5-Day Price Return-2.18%
EPS Normalized (Annual)$-0.80
ROA (5Y Avg)-90.83%
Net Profit Margin (Annual)-349.33%
Month-to-Date Return-7.57%
EBITD / Share (Annual)$-0.62
Operating Margin (Annual)-271.90%
LT Debt / Equity (Annual)0.07x
ROI (5Y Avg)-151.28%
LT Debt / Equity (Quarterly)0.07x
EPS Basic Excl Extra (TTM)$-1.32
P/TBV (Quarterly)10.58x
P/B Ratio (Annual)9.03x
Pretax Margin (TTM)-892.36%
Book Value / Share (Annual)$0.22
Price vs S&P 500 (13W)-23.77%
Beta0.59x
P/FCF (Annual)22.92x
Revenue / Share (TTM)$0.14
ROE (TTM)-316.35%
52-Week Low$0.90
vGradeD
gGradeD
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.75est. -0.14
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.13
4.17
4.16
4.20
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IRDOpus Genetics, Inc. Common Stock | D | D | B | $4.03 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases and other retinal and refractive disorders. Its pipeline includes AAV-based gene therapies for bestrophinopathy, Leber congenital amaurosis, and retinitis pigmentosa, along with small-molecule and ophthalmic solutions for diabetic retinopathy and pupil dysfunction.